Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Mar 25, 2021 (6 years ago)

Metformin HCl Extended-Release Tablets (Metformin Hydrochloride)

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Moisture Limits: Out of specification for water content

Cause type: Failed specification

A physical or chemical test other than potency, dissolution, impurity or stability failed - pH, viscosity, appearance, tablet integrity, fill volume. A product outside its own specification may not perform as designed, even if the active ingredient is present. All failed specification recalls.

What was recalled

Metformin HCl Extended-Release Tablets, USP, 500 mg, Rx Only, 500-count bottle, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512; Manufactured by: Sun Pharmaceutical Industries Ltd., Halol-Baroda HIghway, Halol-389 350 Gujarat, India, NDC 62756-142-02.

Affected NDC 62756-0142-02

Compare with the code on your package — it is the most precise check available.

Drug: Metformin Category: Diabetes Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Metformin Hydrochloride
NDC 62756-0142
500 mg/1 Tablet, Extended Release
Oral
Sun Pharmaceutical Industries, Inc. Rx
Recalling firm
Sun Pharmaceutical Industries INC
NDC code
62756-142-02
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0325-2021 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Metformin recalls

See all
Class II · Moderate risk

Synjardy XR Tablets

CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a different product.

Ongoing cGMP deviation Boehringer Ingelheim Pharmaceuticals, Inc. D-0657-2026

Other recalls by Sun Pharmaceutical Industries INC

All 2021 recalls
Class II · Moderate risk

Carbamazepine Tablets

CGMP Deviations; black spots found on tablets from burnt excipient during manufacturing

Ongoing cGMP deviation Sun Pharmaceutical Industries INC NDC 51672-4005-3 D-0770-2026
Class II · Moderate risk

Perampanel CIII Tablets

Labeling: Label Mix-up: 10mg Perampanel CIII tablet was found in a Perampanel CIII bottle labeled Perampanel 6 mg tablets.

Ongoing Labeling / mix-up Sun Pharmaceutical Industries INC NDC 51672-4206-6 D-0628-2026